1. Folate-receptor alpha (FRα) targeted CDC for the treatment of platinum resistant ovarian cancer

Elucida is developing high potency folate receptor alpha targeted CDCs with topoisomerase 1 (Topo1) inhibitor payloads to create the next generation targeted therapeutics for ovarian cancer. Elucida’s CDCs have the potential to be significantly more potent than current therapies with reduced off-target effects and toxicity that limit existing treatments.

While the initial proof of concept for the FRα-CDC is expected to be established in platinum resistant ovarian cancer, there are several other prevalent tumors that also express the folate receptor alpha antigen. Our FRα-CDC will be studied in these cancer types as well, enabling an expansion in the clinical potential of the lead product. Examples include triple-negative breast, endometrial and non-small cell lung cancers.

Also, given that many additional tumor cell lines are sensitive to the topoisomerase 1 inhibitor drug delivered by our FRα -CDC, we anticipate developing multiple additional CDC candidates with the topoisomerase 1 inhibitor drugs by simply exchanging the folate receptor alpha targeting moiety with other targeting molecules. For example, CDC’s can be made to target pancreatic, colorectal and cervical cancers, all of which are known to be sensitive to the topoisomerase 1 inhibitor, by simply adding different targeting moieties to create exclusive new products for these important cancer indications.

2. CDC for the treatment of brain tumors

Despite advances in treating systemic disease, central nervous system (CNS) metastatic progression is common for many highly prevalent cancer types, including breast and lung cancers. However, advancements in treating CNS malignancies remain sparse due to the limited penetration of drugs and conventional targeted delivery platforms across a variably permeable blood–brain barrier. The unique physicochemical properties of CDCs enable them to effectively cross disrupted blood-brain-barrier (BBB) and diffuse throughout the intratumoral compartment. The resulting improvement in brain tumor delivery and penetration render CDCs a promising platform for the treatment of brain tumors. Elucida is developing brain tumor targeted CDCs with a range of potential potent payloads for the treatment of primary glioma and other brain cancers.